ArticleSignal transduction and targeted therapy2025

RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer.

Zhengyu Zha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.